Photocure ASA
OSE:PHO
Photocure ASA
Pre-Tax Income
Photocure ASA
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Pre-Tax Income
kr8.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Pre-Tax Income
kr80.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Pre-Tax Income
kr5.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Pre-Tax Income
-kr89m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Pre-Tax Income?
Pre-Tax Income
8.4m
NOK
Based on the financial report for Dec 31, 2024, Photocure ASA's Pre-Tax Income amounts to 8.4m NOK.
What is Photocure ASA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-29%
Over the last year, the Pre-Tax Income growth was -14%.
You don't have any saved screeners yet